Insider · CIK 0001400240
Flagship Pioneering, LLC
Files at FHTX (Foghorn Therapeutics Inc.), GENB (Generate Biomedicines, Inc.). First filing -, latest -.
In brief
Flagship Pioneering, LLC files SEC Form 4 as director and 10% owner at FHTX (Foghorn Therapeutics Inc.), and also at GENB (Generate Biomedicines, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Flagship Pioneering, LLC has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 21, 2026 | MRNA Moderna, Inc. | 9,263 0.00% of outstanding | $434k | May 21, 2026 | none |
| Dec 11, 2025 | MRNA Moderna, Inc. | 23,853 0.01% of outstanding | $703k | Dec 11, 2025 | none |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Pre-Funded Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +2,235,468 | $6.71 | $15M | 2,235,468 | Jan 15, 2026 |
| Jan 13, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Series 1 Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +1,117,734 | - | - | 1,117,734 | Jan 15, 2026 |
| Jan 13, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Series 2 Warrants to purchase Common Stockderivativeindirect: By Flagship Pioneering Fund VII, L.P. | +1,117,734 | - | - | 1,117,734 | Jan 15, 2026 |
Questions about Flagship Pioneering, LLC
Answered from the filings on this page, as of the latest one.
Is Flagship Pioneering, LLC buying or selling?
Flagship Pioneering, LLC has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Flagship Pioneering, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Flagship Pioneering, LLC has 0.
Where does Flagship Pioneering, LLC file Form 4?
Flagship Pioneering, LLC has filed Form 4 at FHTX (Foghorn Therapeutics Inc.); GENB (Generate Biomedicines, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.